Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Editas Medicine reports positive clinical data and strategic advancements

Editas Medicine's Q4 2022 earnings call highlighted positive clinical data, strong financial positioning, and strategic advancements in genome editing medicines.
While facing challenges in hiring key personnel, regulatory negotiations, and strategic realignment, the company is well-positioned for therapeutic advancements and market growth.
Opportunities lie in replicating clinical success, strategic partnerships, and advancements in pipeline development, supported by strong collaborations and financial prospects.
Overall, Editas Medicine's performance, strengths, challenges, and opportunities reflect a company poised for continued growth and innovation in the genome editing space.

Editas Medicine excels in Q1 with promising trials and regulatory progress

Editas Medicine's Q1 performance was strong, supported by promising clinical trial data and regulatory advancements.
The company's focus on gene editing for hemoglobinopathies and strong IP position are key strengths.
Challenges include differentiation from competitors and legal uncertainties, while opportunities lie in expansion and regulatory progress.
Overall, Editas Medicine is well-positioned for growth in the gene editing market.

Editas Medicine reports positive data, raises funds, and faces challenges

Editas Medicine shows strong performance with positive clinical data and financial raise
Facing challenges in pipeline adjustment and FDA discussions for facility planning
Opportunities lie in expanding trials, partnerships, and enhancing R&D focus

Editas Medicine advances EDIT-301 program, poised for gene therapy leadership

Editas Medicine is making significant progress with EDIT-301, showcasing confidence in their gene editing capabilities and operational readiness.
While facing challenges in safety monitoring and differentiation, the company's strategic hires, strong IP portfolio, and focus on regulatory pathways provide a solid foundation for growth.
With a clear roadmap for clinical data presentation, manufacturing scaling, and regulatory submissions, Editas is well-positioned to capitalize on opportunities in gene editing therapies.

Editas Medicine exceeds enrollment goals and showcases promising clinical data

Editas Medicine's Q4 2023 Earnings Call showcased strong performance in enrollment, clinical data, and financials. The company's strengths lie in its research capabilities, cash position, and progress in key trials. Challenges include addressing analyst queries and optimizing manufacturing processes.

Editas Medicine reports robust Q1 performance and advances in gene editing

Editas Medicine's Q1 2024 performance reflects solid revenue and strong financial reserves, driven by R&D investments in the Renace program.
The company's strengths lie in its financial stability, advancing in vivo capabilities, and fostering strong collaborations for future growth.
Challenges include legal uncertainties, operational optimizations, and strategic complexities in therapeutic development.
Opportunities abound in driving Renace, regulatory progress for Reni-cel, and leveraging innovative in vivo approaches for unique indications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Editas Medicine, Inc. (NASDAQ:EDIT ) Q2 2022 Earnings Conference Call August 3, 2022 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Jim Mullen - Executive Chairman Gilmore O'Neill - Chief Executive Officer Mark Shearman - Chief Scientific Officer Michelle Robertson - Chief Financial Officer Baisong Mei - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Joon Lee - Truist Securities Dae Gon Ha - Stifel Jay Olson - Oppenheimer Luca Issi - RBC Capital Markets Rick Bienkowski - SVB Securities Philip Nadeau - Cowen and Company Joel Beatty - Robert W. Baird Yanan Zhu - Wells Fargo Securities Ryan Deschner - Raymond James Operator Good morning and welcome to Editas Medicine's Second Quarter 2022 Conference Call.

Editas Medicine, Inc. (EDIT) CEO Gilmore O'Neill on Q2 2022 Results - Earnings Call Transcript

The company's top line really caught investors' eye.

Why Editas Medicine Was Winning on Wednesday

Editas (EDIT) delivered earnings and revenue surprises of 7.14% and 19.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

Appointed Baisong Mei, M.D., Ph.D., Chief Medical Officer, strengthening senior leadership team

Editas Medicine Announces Second Quarter 2022 Results and Business Updates

Successful engraftment of first patient dosed with EDIT-301 for sickle cell disease

Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 3, 2022, at 8:00 a.m. ET to provide financial results and corporate updates for the second quarter of 2022.

Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates

This biotech could be a steal at its current levels, but it could also be a trap.

Down 35% This Year, Is This Small-Cap Stock a Buy?

CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of an inducement award to the Company's newly appointed Chief Medical Officer, Baisong Mei, M.D., Ph.D. In connection with Dr. Mei's appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. Mei as an inducement material to Dr. Mei entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option provides for the purchase of up to 171,602 shares of Editas Medicine common stock at a price of $14.99 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Dr. Mei's employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Dr. Mei's continued service relationship with Editas Medicine through the applicable vesting dates.

Editas Medicine Reports Inducement Grant to New Chief Medical Officer

CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of Baisong Mei, M.D., Ph.D., as the Company's Senior Vice President and Chief Medical Officer, effective immediately. Dr. Mei will lead clinical research and drug development for the Company's pipeline of experimental medicines across all therapeutic indications, including hematology, oncology, and ophthalmology.

Editas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer

Beam Therapeutics

Vertex Pharmaceuticals

There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. The post The 3 Leaders of the Gene Editing Revolution appeared first on InvestorPlace.

The 3 Leaders of the Gene Editing Revolution

Biogen

CRISPR Therapeutics

Intellia Therapeutics

Regeneron Pharmaceuticals

Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on InvestorPlace.

7 Moonshot Investments Upending a $10 Trillion Industry

Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

Montrose Environmental Group, Inc.

Replimune Group Inc

Following a stronger-than-expected jobs report for June, U.S. market indexes rose on Friday as investors anticipate the Federal Reserve will continue with its aggressive interest rate hikes as it attempts to combat inflation.

3 Lost Formula Stocks to Consider for July

bluebird bio

These high-tech biotech stocks made a sharp U-turn this week after a rough start to the year.

Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This Week

TUEBINGEN, Germany and HOUSTON and CAMBRIDGE, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc. (Nasdaq: EDIT, “Editas Medicine”), a leading genome editing company, today announced that the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta T cell adoptive cell therapies and gene editing to develop medicines for the treatment of cancer. As part of the licensing agreement, Immatics gains non-exclusive rights to Editas Medicine's CRISPR technology and intellectual property. Editas Medicine is the exclusive licensee of Harvard and Broad Institute's Cas9 patent estates and Broad Institute's Cas12a patent estate for human medicines.

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer

Results from the phase 1/2 BRILLIANCE study using EDIT-101 in patients with LCA10 are expected in the second half of 2022. Editas was the clear winner with respect to Broad winning the patent dispute case over Crispr patents back in February of 2022; This could change with appeals and other courts.

Editas: Tackling Rare Eye Disease With Use Of Crispr Technology

CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company's newly appointed President and Chief Executive Officer, Gilmore O'Neill, M.B., M.M.Sc. As previously announced, Dr. O'Neill joined the Company on June 1, 2022, in his new role. In connection with Dr. Gilmore's appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. O'Neill as an inducement material to Dr. O'Neill entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option provides for the purchase of up to 950,209 shares of Editas Medicine common stock at a price of $11.54 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Dr. O'Neill's employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Dr. O'Neill's continued service relationship with Editas Medicine through the applicable vesting dates.

Editas Medicine Reports Inducement Grants to New Chief Executive Officer

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

Editas (EDIT) Down 20.7% Since Last Earnings Report: Can It Rebound?

ARK Genomic Revolution Multi-Sector ETF

Burning Rock Biotech

Ionis Pharma

Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?

Cathie Wood Is Selling Gene Editing Stocks. Here's Why.

SLEEK results in highly efficient multi-transgene knock-in and enables tunability of transgene expression

Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting

The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.

Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia

The company's progress for its lead therapy has been slow.

Why Editas Medicine's Shares Fell 28.9% This Week

Company on track to dose first transfusion-dependent beta thalassemia patient with EDIT-301 by year-end Company on track to dose first transfusion-dependent beta thalassemia patient with EDIT-301 by year-end

Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia

Editas (EDIT) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates. Focus on lead candidate, EDIT-101.

Editas' (EDIT) Q1 Loss Narrows, Revenues Beat Estimates

Studies in non-human primates demonstrated nearly 100% gene editing knockout of endogenous RHO gene and more than 30% replacement protein levels

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference

News for Editas Medicine Stock (EDIT)